Relieve the patient's cardiac symptoms within two weeks Jixing Pharmaceutical owns R&D rights in Greater China

On July 19, 2021, Cytokinetics announced that in patients with obstructive hypertrophic cardiomyopathy (oHCM), its new drug CK-274 has achieved positive top lines in both dose cohorts of phase 2 clinical trials.

The results of this trial provide valuable dose selection information for its planned phase 3 trial, which is expected to start enrollment before the end of the year

HCM is a disease in which the heart muscle becomes abnormally thick

In this multicenter, randomized double-blind, dose-escalation, placebo-controlled Phase 2 REDWOOD-HCM trial, patients were randomly assigned to the CK-274 group or the placebo group at a ratio of 2:1

▲Dose titration used in the experiment (picture source: reference [1])

The results of the test showed that in patients with symptomatic obstructive HCM, compared with placebo, after 10 weeks of treatment with CK-274, the average resting LVOT-G of patients and after the use of eustachian tube inflation test (Valsalva maneuver) The average LVOT-G of LVOT-G showed a statistically significant decrease compared with the baseline

▲The average resting LVOT-G data of patients (picture source: reference [1])

Compared with the placebo group (7.

In terms of safety, CK-274 administration is generally well tolerated

Note: The original text has been deleted

Reference materials:

[1] Cytokinetics Announces Positive Topline Results of Redwood-HCM.

[2] Troubled Cytokinetics' stock soars as gets much needed phase 2 heart drug trial win, plans late-stage effort by year's end.